PRESS-NEWS.org - Press Release Distribution
PRESS RELEASES DISTRIBUTION

Penn researchers discover drug that blocks multiple SARS-CoV-2 variants in mice

2021-05-28
(Press-News.org) The drug diABZI -- which activates the body's innate immune response -- was highly effective in preventing severe COVID-19 in mice that were infected with SARS-CoV-2, according to scientists in the Perelman School of Medicine at the University of Pennsylvania. The findings, published this month in Science Immunology, suggest that diABZI could also treat other respiratory coronaviruses.

"Few drugs have been identified as game-changers in blocking SARS-CoV-2 infection. This paper is the first to show that activating an early immune response therapeutically with a single dose is a promising strategy for controlling the virus, including the South African variant B.1.351, which has led to worldwide concern," said senior author Sara Cherry, PhD, a professor of Pathology and Laboratory Medicine and scientific director of the High-Throughput Screening (HTS) Core at Penn Medicine. "The development of effective antivirals is urgently needed for controlling SARS-CoV-2 infection and disease, especially as dangerous variants of the virus continue to emerge."

The SARS-CoV-2 virus initially targets epithelial cells in the respiratory tract. As the first line of defense against infection, the respiratory tract's innate immune system recognizes viral pathogens by detecting their molecular patterns. Cherry and her research team first sought to better understand this effect by observing human lung cell lines under the microscope that had been infected with SARS-CoV-2. They found that the virus is able to hide, delaying the immune system's early recognition and response. The researchers predicted that they may be able to identify drugs -- or small molecules with drug-like properties -- that could set off this immune response in the respiratory cells earlier and prevent severe SARS-CoV-2 infection.

To identify antiviral agonists that would block SARS-CoV-2 infection, the researchers performed high throughput screening of 75 drugs that target sensing pathways in lung cells. They examined their effects on viral infection under microscopy and identified nine candidates --including two cyclic dinucleotides (CDNs) -- that significantly suppressed infection by activating STING (the simulation of interferon genes).

Since CDNs have low potency and make poor drugs, according to Cherry, she and her team decided to also test a newly-developed small molecule STING agonist called diABZI, which is not approved by the Food and Drug Administration but is currently being tested in clinical trials to treat some cancers. The researchers found that diABZI potently inhibits SARS-CoV-2 infection of diverse strains, including variant of concern B.1.351, by stimulating interferon signaling.

Finally, the researchers tested the effectiveness of diABZI in transgenic mice that had been infected with SARS-CoV-2. Because the drug needed to reach the lungs, diABZI was administered through a nasal delivery. diABZI-treated mice showed much less weight loss than the control mice, had significantly-reduced viral loads in their lungs and nostrils, and increased cytokine production -- all supporting the finding that diABZI stimulates interferon for protective immunity.

Cherry said that the study's findings offer promise that diABZI could be an effective treatment for SARS-CoV-2 that could prevent severe COVID-19 symptoms and the spread of infection. Additionally, since diABZI has been shown to inhibit human parainfluenza virus and rhinovirus replication in cultured cells, the STING agonist may be more broadly effective against other respiratory viruses.

"We are now testing this STING agonist against many other viruses," Cherry said. "It's really important to remember that SARS-CoV-2 is not going to be the last coronavirus that we will see and will need protection against."

INFORMATION:



ELSE PRESS RELEASES FROM THIS DATE:

Seropositivity following mRNA vaccination for SARS-CoV-2 in patients undergoing cancer treatment

2021-05-28
What The Study Did: Rates of antispike antibody response to a messenger RNA SARS-CoV-2 vaccine in Israeli patients with cancer who are undergoing systemic treatment compared with healthy controls were evaluated in this study. Authors: Salomon M. Stemmer, M.D., of the Rabin Medical Center in Petah Tikva, Israel, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/  (doi:10.1001/jamaoncol.2021.2155) Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, ...

SARS-CoV-2 antibody status in patients with cancer, health care workers

2021-05-28
What The Study Did: This study evaluates whether there are differences in SARS-CoV-2 seroprevalence and antibody levels in patients with cancer compared with health care workers in Japan. Authors: Tatsuya Yoshida, M.D., Ph.D., of the National Cancer Center Hospital in Tokyo, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/  (doi:10.1001/jamaoncol.2021.2159) Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see ...

Socioeconomic disparities in respiratory health in US

2021-05-28
What The Study Did: Socioeconomic disparities in respiratory health over the past six decades in the United States are described in this study. Authors: Adam W. Gaffney, M.D., of the Cambridge Health Alliance in Cambridge, Massachusetts, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamainternmed.2021.2441) Editor's Note: The article includes conflicts of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support. #  #  ...

Assessment of SARS-CoV-2 reinfection 1 year after primary infection in Lombardy, Italy

2021-05-28
What The Study Did: Study results suggest that reinfections are rare events and that patients who have recovered from COVID-19 have a lower risk of reinfection. However, the observation ended before SARS-CoV-2 variants began to spread, and it is unknown how well natural immunity to the wild-type virus will protect against variants. . Authors: Nicola Mumoli, M.D., of the Ospedale Fornaroli in Magenta, Italy, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamainternmed.2021.2959) Editor's ...

Examining well-being, life expectancy with having family member incarcerated

2021-05-28
What The Study Did: This survey study examined the associations of having an incarcerated immediate or extended family member with perceived well-being and change in projected life expectancy among adults in the United States. Authors: Ram Sundaresh, M.D., M.S., of the University of California, Los Angeles, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamanetworkopen.2021.11821) Editor's Note: The article includes conflicts of interest and funding/support disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict ...

Applying private insurer rules to Medicare Part B

2021-05-28
What The Study Did: Researchers estimated the extent Medicare Part B medical services would have been subject to prior authorization under private insurance coverage policies and calculated the associated spending. Authors: Aaron L. Schwartz, M.D., Ph.D., of the University of Pennsylvania in Philadelphia, is the corresponding author. To access the embargoed study:  Visit our For The Media website at this link https://media.jamanetwork.com/  (doi:10.1001/jamahealthforum.2021.0859) Editor's Note: The article includes conflict of interest and funding/support disclosures. Please see the article for additional information, including other authors, author ...

Social connectedness among medicare beneficiaries after onset of pandemic

2021-05-28
What The Study Did: Researchers examined social connectedness among Medicare beneficiaries during the COVID-19 pandemic. Authors: Wesley John Talcott, M.D., M.B.A., the Yale School of Medicine in New Haven, Connecticut, is the corresponding author. To access the embargoed study: Visit our For The Media website at this link https://media.jamanetwork.com/ (doi:10.1001/jamainternmed.2021.2348) Editor's Note: The article includes conflict of interest disclosures. Please see the article for additional information, including other authors, author contributions and affiliations, conflict of interest and financial disclosures, and funding and support. INFORMATION: Media advisory: The full study is linked to this news release. Embed this link to provide your readers free ...

Providing more low-value care doesn't lead to higher patient experience ratings

2021-05-28
As hospitals, insurance companies and policy makers seek to improve healthcare quality and reduce rising medical costs, one important metric used to assess clinicians hinges on how patients feel about their healthcare experience. Many healthcare providers and policy makers fear that increased pressure to please patients -- and ensure high satisfaction ratings as a result -- could lead to overuse of low-value care that doesn't provide any clinical benefit while unnecessarily ratcheting up medical bills. But new research from the University of Chicago and Harvard Medical School may alleviate some of those concerns. The study, published May 28 in END ...

ECOG-ACRIN research highlights at ASCO 2021

2021-05-28
New research results for patients with breast and HPV-associated throat cancers are the highlights among 23 presentations by ECOG-ACRIN Cancer Research Group researchers at the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting, occurring virtually June 4-8. The National Cancer Institute (NCI), part of the National Institutes of Health, funded these studies. Breast Cancer Platinum chemotherapy fails in phase III trial for triple-negative breast cancer, basal-like subtype Abstract 605: About 80% of triple-negative breast cancers (TNBC) are a subtype called 'basal-like.' ...

Stem cell drugs surprise researchers: Could lead to better drugs in the future

2021-05-28
Your immune system is always busy fighting incoming threats. It consists of a system of cells, and when there is a shortage of cells, it affects the performance of the immune system. This is seen in e.g. cancer patients following chemotherapy. This is because chemotherapy targets all the cells in your body, including the stem cells in your bone marrow, which were meant to develop into new immune cells. This means that the immune system then lacks cells to fight new infections. There are drugs that can harvest stem cells from the bone marrow, so that they can be returned to the patients after treatment. They then develop into new immune cells, enabling the body to once again fight incoming threats. But previously, we lacked ...

LAST 30 PRESS RELEASES:

Andrew E. Place, MD, PhD appointed as Dana-Farber/Boston Children’s Cancer and Blood Disorders Center Vice President, Pediatric Chief Medical Officer

COVID-19 antibody discovery could explain long COVID

Wild plants face viral surprise

Storing electrons from hydrogen for clean chemical reactions

Unlocking how to use mRNA to target Alzheimer’s disease

Kessler Foundation secures $770,000 in grants to advance leading-edge spinal cord research

Going ‘back to the future’ to forecast the fate of a dead Florida coral reef

How extratropical ocean-atmosphere interactions can contribute to the variability of jet streams in the Northern Hemisphere

MSK Research Highlights, March 28, 2024

USDA, Nueta Hidatsa Sahnish College collaborate to support Indigenous Seed Sovereignty

For younger women, mental health now may predict heart health later

Missed opportunity: AEDs near cardiac arrests rarely used by bystanders

Eggs may not be bad for your heart after all

Alcohol raises heart disease risk, particularly among women

TTUHSC announces new center for nursing research

Adding just enough fuel to the fire

Impact of synbiotic supplements on the gut microbiome and overall health of penguins

Promising advances in organosilica membranes for separating organic liquid mixtures

Cell phone video technology unveils new method for analyzing walking and gait

Ancient isolation’s impact on modern ecology

Synaptic protein change during development offers clues on evolution and disease

How commercial rooftop solar power could bring affordable clean energy to low-income homes

Taking a closer look at pulmonary fibrosis genetics

Cats with MDR1 mutation at risk of severe reactions to popular medication

IOP Publishing and IPEM mandate reporting of sex and gender in research 

Dogs trained to detect trauma stress by smelling humans’ breath

Electronic device thermal management made simpler and slightly better!

Study: Dangerous surgical site infections can be reduced with simple prevention protocol

Genetic testing of patients with atrial fibrillation can alert clinicians to potential development of life-threatening conditions

Artificial Intelligence tool successfully predicts fatal heart rhythm

[Press-News.org] Penn researchers discover drug that blocks multiple SARS-CoV-2 variants in mice